Related references
Note: Only part of the references are listed.
Article
Pharmacology & Pharmacy
Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies
James F. Sigafoos et al.
DRUG METABOLISM AND DISPOSITION (2012)
Article
Endocrinology & Metabolism
Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes
Joseph W. Polli et al.
JOURNAL OF DIABETES & METABOLISM (2012)
Article
Pharmacology & Pharmacy
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)